Introduction Medications for opioid use disorder (MOUD) are evidence-based treatments, yet
can be controversial among some populations. This study provides a systematic review of …

Background Human beings have long consumed opiates and opioids for pleasure and as a
treatment for numerous ailments, most notably pain. North America is currently in the grips of …

Individuals with a substance use disorder (SUD) often have fewer social support network
resources than those without SUDs. This qualitative study examined the role of social …

Background Historical restrictions on take-home medications for opioid use disorder have
generated considerable debate. The COVID-19 pandemic shifted the perceived risks and …

Objective To advise physicians on which treatment options to recommend for specific patient
populations: abstinence-based treatment, buprenorphine-naloxone maintenance, or …

Aims We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD),
specifically methadone and buprenorphine, including buprenorphine‐naloxone, is delivered …

Background The loosening of US methadone regulations during the COVID-19 pandemic
expanded calls for methadone reform. This study examines professional perceptions of …

Background Opioid dependence (OD) is an increasing clinical and public health problem
worldwide. International guidelines recommend opioid substitution treatment (OST), such as …

Non-medical use of opioid analgesics (OAs) has increased in the United States over the
past decade. Concurrently, access to opioid agonist therapies (OATs) such as …

Background The COVID-19 pandemic led to an unprecedented relaxation of restrictions on
take-home doses in opioid agonist treatment (OAT). We conducted a mixed methods …